High grade dollar bond investors are braced for the biggest deal of the year after AbbVie, the pharmaceutical company, appointed a trio of banks to lead a possible $25bn issue that could come as soon as Monday.
AbbVie’s $63bn acquisition of Allergan received shareholder approval on October 25 and the company engaged Bank of America, Barclays and Morgan Stanley for investor calls on November 7 and 8. “While deal magnitude could present a technical headwind, we expect healthy demand for an IG pharma offering coming
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com
Or sign up for a trial to gain full access to the entire site for a limited period.
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: firstname.lastname@example.org or find out more online here.